A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

NCT04350463 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: CC-90011
DRUG: Nivolumab

Sponsor

Celgene